Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial

IMPORTANCE: The dupilumab regimen of 300 mg every 2 weeks is approved for uncontrolled, moderate to severe atopic dermatitis (AD). OBJECTIVE: To assess the efficacy and safety of different dupilumab regimens in maintaining response after 16 weeks of initial treatment. DESIGN, SETTING, AND PARTICIPAN...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:JAMA Dermatol
Główni autorzy: Worm, Margitta, Simpson, Eric L., Thaçi, Diamant, Bissonnette, Robert, Lacour, Jean-Philippe, Beissert, Stefan, Kawashima, Makoto, Ferrándiz, Carlos, Smith, Catherine H., Beck, Lisa A., Chan, Kuo-Chen, Chen, Zhen, Akinlade, Bolanle, Hultsch, Thomas, Staudinger, Heribert, Gadkari, Abhijit, Eckert, Laurent, Davis, John D., Rajadhyaksha, Manoj, Graham, Neil M. H., Pirozzi, Gianluca, Stahl, Neil, Yancopoulos, George D., Ardeleanu, Marius
Format: Artigo
Język:Inglês
Wydane: American Medical Association 2019
Hasła przedmiotowe:
Original Investigation
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6990756/
https://ncbi.nlm.nih.gov/pubmed/31876900
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamadermatol.2019.3617
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy